Investor Presentaiton
•
.
•
R&D investment lays foundation for future growth
Research and development expenditure*
$NZ Million
$14.0
$12.0
$2.5
$10.0
$8.0
$6.0
$6.0
SALINE
$7.2
20
$9.5
$1.5
$4.0
$2.4
$2.0
$4.1
$3.4
$2.0
$2.8
$-
FY2018
FY2019
FY2020
FY2021
1H 2022
Expensed R&D costs
Capitalised R&D costs
Maxigesic dose forms:
-
Maxigesic Cold & Flu final studies underway this year
Pascomer: Treatment of facial angiofibromas
-
Licensed for North America to Timber Pharmaceuticals and Europe to Desitin
Global Phase II/III study patient enrolment closed now despite the pandemic
NasoSURF: Intranasal drug delivery instead of an injection
-
Clinical studies of the first dose form to commence in FY22
Other products:
Other products in development: Medicinal Cannabis, Crystawash Extend,
Crystaderm
AFTpharmaceuticals
*Research and development costs also include new market development costs.
CRYSTAWASH
EXTEND
CRYSTAWASH
Hand Sanitiser
EXTEND
Hand Sanitiser
Sanitises and protects against
99.99% of germs
Lasts for up to 24 hrs
500
Page 12View entire presentation